Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera has a late-stage development pipeline in orphan indications. The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, and Primary Progressive Multiple Sclerosis. Omigapil, a second compound, is in clinical development to treat Congenital Muscular Dystrophy.
Learn more about our products and pipeline

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ/CatenaŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being conducted to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

August 19, 2015
Santhera Receives Rare Pediatric Disease Designation from FDA for Idebenone for the Treatment of Duchenne Muscular Dystrophy
---
August 07, 2015
Santhera Raised CHF 27.7 Million of New Capital
---
July 31, 2015
Santhera to Raise Capital Through Sale of Newly Created Shares